Sarepta Therapeutics (NASDAQ:SRPT) Issues Earnings Results, Beats Expectations By $0.42 EPS

Sarepta Therapeutics (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42, FiscalAI reports. The firm had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The firm’s quarterly revenue was down 34.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.02 earnings per share.

Here are the key takeaways from Sarepta Therapeutics’ conference call:

• 2026 net product revenue guidance was narrowed to $1.2 billion–$1.3 billion, with second-half revenue expected to be modestly below the first half and ELEVIDYS revenue likely lower in the third quarter. Management said improving enrollment forms may contribute more meaningfully to revenue in 2027.
• Sarepta reported Q2 GAAP operating income of $13 million and non-GAAP operating income of $86 million, while cash and investments increased by approximately $197 million to $945 million. The company also raised collaboration and other revenue guidance to $550 million–$600 million, primarily due to higher Roche contract-manufacturing revenue.
• ELEVIDYS enrollment-form activity improved sequentially as the expanded commercial organization became fully operational, with increased engagement from returning sites and interest from new referral sites. However, management cautioned that the typical approximately six-month enrollment-to-infusion timeline delays the revenue impact.
• The FDA accepted supplemental applications for AMONDYS 45 and VYONDYS 53 seeking conversion from accelerated to traditional approval, with a target action date of February 28, 2027. Sarepta said the applications are supported by the ESSENCE confirmatory study and substantial real-world evidence.
• Key pipeline catalysts include second-half 2026 interim MAD-study data for the SRP-1001 FSHD and SRP-1003 DM1 programs, early Huntington’s disease proof-of-biology data expected in early 2027, and full 12-week data from ELEVIDYS ENDEAVOR cohort 8 expected in the first quarter of 2027.

Sarepta Therapeutics Price Performance

Shares of SRPT traded down $0.46 during mid-day trading on Wednesday, hitting $15.93. 3,080,925 shares of the company were exchanged, compared to its average volume of 3,160,738. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -16.59, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23. Sarepta Therapeutics has a 1-year low of $14.68 and a 1-year high of $25.32. The company has a 50 day moving average of $16.95 and a 200-day moving average of $18.55. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.62 and a current ratio of 4.63.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Sarepta reported second-quarter 2026 adjusted earnings of $0.64 per share, exceeding estimates ranging from $0.22 to $0.58. Revenue of $401.25 million also surpassed the $366.39 million consensus estimate, producing earnings and revenue surprises of approximately 10.35% and 12.85%, respectively. Sarepta Therapeutics Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company highlighted approximately $328.7 million in product revenue and said its rare-disease medicines continue to support its commercial foundation. New CEO Michael Severino also pointed to potential opportunities ahead as he begins his tenure. Sarepta Announces Second-Quarter Results and Corporate Developments
• Neutral Sentiment: The earnings release included recent corporate developments, but the available reports did not identify a major new guidance change or specific catalyst likely to materially alter near-term forecasts. Sarepta Therapeutics Announces Second-Quarter 2026 Financial Results
• Negative Sentiment: Despite beating estimates, revenue fell 34.3% year over year from $2.02 per share in the prior-year quarter, while the latest earnings result was substantially below the year-ago level. The weaker underlying trend likely outweighed the quarterly beat for investors. Sarepta Therapeutics Quarterly Earnings Results

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 454.6% in the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares in the last quarter. Amundi increased its position in shares of Sarepta Therapeutics by 378.2% during the third quarter. Amundi now owns 969,826 shares of the biotechnology company’s stock worth $18,689,000 after purchasing an additional 767,026 shares in the last quarter. Millennium Management LLC raised its stake in Sarepta Therapeutics by 251.9% in the 4th quarter. Millennium Management LLC now owns 1,000,109 shares of the biotechnology company’s stock valued at $21,522,000 after purchasing an additional 715,899 shares during the last quarter. Invesco Ltd. raised its stake in Sarepta Therapeutics by 242.0% in the 3rd quarter. Invesco Ltd. now owns 832,638 shares of the biotechnology company’s stock valued at $16,045,000 after purchasing an additional 589,157 shares during the last quarter. Finally, Opaleye Management Inc. purchased a new position in Sarepta Therapeutics in the 2nd quarter valued at $8,550,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 4th. Royal Bank Of Canada lifted their price target on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research note on Tuesday, April 7th. Zacks Research cut Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, July 9th. Finally, HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and six have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $24.72.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.